About Anti-Human CD317 (BST2/Tetherin) Monoclonal Antibody

CD317, also known as BST2 (Bone Marrow Stromal Cell Antigen 2), Tetherin, or HM1.24, is a type II transmembrane glycoprotein that functions as an interferon-inducible antiviral restriction factor. CD317 inhibits the release of numerous enveloped viruses—including HIV-1, Ebola virus, Marburg virus, Lassa virus, and SARS-related coronaviruses—by physically tethering newly budded virions to the cell surface, thereby preventing viral dissemination. In addition to its antiviral activity, CD317 participates in innate immune signaling through NF-κB activation and is expressed on a variety of immune cells, plasma cells, and several human malignancies, making it an important biomarker and therapeutic target.

eEnzyme's Anti-Human CD317 (BST2/Tetherin) Monoclonal Antibody is a high-quality mouse monoclonal antibody that specifically recognizes human CD317. The antibody is suitable for Western blotting, ELISA, immunofluorescence (IF), immunocytochemistry (ICC), immunoprecipitation (IP), and flow cytometry (when applicable). It provides a reliable reagent for detecting endogenous or recombinant CD317, investigating virus-host interactions, evaluating interferon responses, and supporting studies of antiviral immunity, cancer biology, and therapeutic antibody development.

Applications

Biological Significance of CD317 (BST2/Tetherin)

CD317 is one of the most important host restriction factors involved in innate antiviral defense. Following induction by type I interferons, CD317 prevents the release of newly formed enveloped viruses by anchoring virions to the plasma membrane, thereby limiting viral spread. To overcome this restriction, many viruses have evolved antagonistic proteins, such as HIV-1 Vpu and Ebola virus glycoprotein, that counteract CD317 function. Beyond its antiviral role, CD317 regulates innate immune signaling, cell adhesion, and inflammatory responses, and is highly expressed in multiple myeloma, certain leukemias, and several solid tumors, making it a valuable target for both infectious disease and cancer research.

The Anti-Human CD317 (BST2/Tetherin) Monoclonal Antibody provides a robust research tool for investigating CD317 expression and function, characterizing antiviral restriction mechanisms, monitoring interferon-induced responses, and supporting the development of antiviral therapeutics, immunotherapies, and cancer-targeted antibody strategies.